Menstrual migraine (catamenial migraine)

Characteristics and typical features

Compared with migraine at other times of the cycle, menstrual attacks are often longer in duration and can be more resistant to standard short-term therapies. They are most commonly migraine without aura, though aura can occur in some cases. Symptoms mirror those of other migraines: moderate to severe unilateral or bilateral head pain, pulsating quality, sensitivity to light or sound, nausea, and sometimes vomiting. Many patients report a predictable pattern, with attacks beginning within a few days before to a few days after the start of menstruation.

Causes and physiological basis

Hormonal change is the principal trigger: the rapid decline in circulating estrogen just before menses is believed to lower the threshold for cortical excitability and activation of pain pathways. Other contributors can include sleep disruption, stress, menstrual-related changes in iron or prostaglandins, and concurrent use or withdrawal of hormonal contraceptives. Research on the precise mechanisms continues; for general prevalence information see prevalence studies.

Diagnosis and classification

Diagnosis relies on history, timing and pattern of attacks. A prospective headache diary kept over several cycles is often used to confirm the relationship to menses. Historically menstrual migraine has been separated from other migraine types in classification systems to reflect its distinct timing and treatment challenges; many diagnostic guides recommend tracking frequency and response to therapies. Typical educational resources explain the difference between migraine with and without aura; see an overview at aura information. For sensory and other neurological features associated with aura consult sensory symptom sources or speech and motor descriptions.

Treatment and management

Management strategies fall into acute (symptomatic) and preventive approaches. Acute options include analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs) and triptans; however, menstrual attacks may respond less well to single-dose acute treatments. Short-term preventive (perimenstrual) therapy — giving a preventive agent around the time of anticipated menses — can reduce attack frequency and severity. Hormonal strategies aimed at stabilizing estrogen levels, such as continuous or extended-cycle contraceptive regimens or short courses of transdermal estrogen at menses, are sometimes used when appropriate. Choice of treatment is individualized, balancing efficacy, side effects and reproductive plans.

Importance and notable facts

Menstrual migraine affects a meaningful proportion of women with migraine and can have substantial impact on quality of life because of predictability, duration and therapeutic difficulty. Estimates suggest that only a minority of female migraine sufferers experience attacks exclusively at menstruation, while many more have a perimenstrual increase in attacks. Accurate recognition helps clinicians plan timed preventive care and behavioural strategies such as sleep hygiene and trigger avoidance. For additional clinical guidance and population data see linked resources above.

• Key distinctions: true menstrual migraine vs. menstrually related migraine.
• Typical timing: attacks cluster in the late luteal to early follicular phase.
• Management often requires a combination of acute treatment and short-term or hormonal prevention.